Guangdong Kangmei Pharmaceutical To Set Up Subsidiary For Ginseng Business
This article was originally published in PharmAsia News
Executive Summary
Guangdong Kangmei Pharmaceutical will establish a wholly owned RMB 400 million subsidiary in Ji'an city, Jilin province to serve as a platform to complete the company's plan in the main ginseng-growing area and extend its network. With registered capital of RMB 100 million, the new set-up will mainly focus on the ginseng business, class II and III TCM, as well as local herbal planting and processing. In addition, the subsidiary plans to buy out Ji'an City Xinkaihe's assets and liabilities with less than RMB 200 million. Xinkaihe is an ginseng farming, processing, sales and R&D company. Kangmei believes the move will further optimize its resource allocation and increase revenue by RMB 120 million - 150 million in 2009. (Click here for more - Chinese Language)
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.